Transparency Market Research
Use of Peptide Therapeutics in Treatment of Diverse Medical Conditions Stimulates Market Growth
Buy Now Request Sample
Published Date: Aug 2013
and Forecast, 2013 - 2019 Single User License: US $ 4595 Multi User License: US $ 7595
104 Pages Report
Corporate User License: US $ 10595 REPORT DESCRIPTION Use of Peptide Therapeutics in Treatment of Diverse Medical Conditions Stimulates Market Growth: Transparency Market Research According to a new market study released by Transparency Market Research (TMR), the global peptide therapeutics market will be valued at US$23.7 bn by 2020, increasing from its 2013 valuation of US$18.9 bn. If the projected figure hold true, the market will rise at a moderate 2.8% CAGR from 2014 to 2020. The report is titled “Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020� and is available for sale on the company website. Browse the full Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 report at http://www.transparencymarketresearch.com/peptide-therapeutics-market.html
Therapeutic peptides have received acceptance in the treatment of several diseases such as metabolic disorders, cancer, nervous system disorders, gastrointestinal disorders, acromegaly, hematological disorders, cardiovascular disorders, infections, and respiratory
disorders, among others. Due to the efficacy of peptides for the treatment of a large number of medical conditions, further research and development has resulted in a rich pipeline of novel peptides that deliver better therapeutic effects. Though animal sources such as venom constitute the major source for peptide research, microbial sources are also being examined for their efficacy for treatment of various medical conditions. The growing variety of sources as well as applications of peptide therapeutics is boosting growth prospects of the global peptide therapeutics market. However, despite extensive research, oral administering of therapeutic peptides still remains a challenge for researchers, which is indirectly hampering the peptide therapeutics market. Unfavorable physiological conditions such as the presence of proteolytic enzymes and acidic pH pose a challenge for oral administering of peptide therapeutics. Moreover, low intestinal penetrability of peptides also adds to the low bioavailability of these substances. Lately, a strong trend has been observed in the peptide therapeutics market: whilst new peptide therapeutic drugs receive regulatory permission, several older peptide therapeutic drugs will go off-patent during the forecast period. In addition, difficulties associated with imitating the precise effects of biologics are a major reason for generic drug manufacturers to face drug approval issues. Thus, generic peptide therapeutic drugs are priced only 70-80% as much as branded peptide therapeutics. Due to this price gap, high demand for generic versions is expected to help the peptide therapeutics market overcome its restraints. Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418 Presently, the generic peptide therapeutic leuprolide is retailed under the brand names Eligard, Lupron, and Enantone, of which Lupron and Enantone constitute sales over US$800 mn across the world.On the competitive front, currently, Teva Pharmaceutical Industries Ltd., Novo Nordisk, and Takeda Pharmaceutical Co. Ltd. collectively account for more than 50% of the global peptide therapeutics market. However, the patent expiration of Copaxone in 2014 and Velcade in 2017 will lead to launch of their generic alternatives. Some other prominent players in the global peptide therapeutics market are AstraZeneca plc, Eli Lilly & Co., Merck & Co., Novartis International, and AbbVie Inc. The global peptide therapeutics market has been segmented as below: Global Peptide Therapeutics Market, by Application o Cancer Zoladex (goserelin) Velcade (bortezomib) Lupron/ Enantone/ Eligard (leuprorelin) Others o Cardiovascular Angiomax (bivalirudin) Integrilin (eptifibatide)
Central Nervous System Copaxone (glatiramer) o Metabolic Disorders Victoza (liraglutide) Byetta (exenatide) Others o Infection Incivek (telaprevir) Victrelis (boceprevir) o Hematological Disorders Firazyr (icatibant) Kalbitor (ecallantide) o Gastrointestinal Disorders Gattex (teduglutide) Linzess (linaclotide) o Respiratory Disorders o Acromegaly o Other Applications Global Peptide Therapeutics Market, by Route of Administration o Parenteral o Oral Global Peptide Therapeutics Market, by Marketing Status o Branded o Generic Global Peptide Therapeutics Market, by Geography o North America o Europe o Asia Pacific o Rest of the World o
Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418 Table of content Chapter 1 Introduction 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.4 List of Abbreviations 1.5 Assumptions and Stipulations Chapter 2 Executive Summary 2.1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020) 2.2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)
Chapter 3 Global Peptide Therapeutics Market Overview 3.1 Introduction 3.2 Emerging Trends in Peptide Therapeutics Market 3.2.1 Trends in Peptide Manufacturing Technology 3.2.2 Trends in Peptide API Supply 3.3 Market Dynamics 3.3.1 Drivers 3.3.1.1 Increase in cancer and diabetes patient population to propel the growth of new peptides 3.3.1.2 Rich R&D pipeline of peptide drugs is expected to drive growth 3.3.1.3 Technological advancements have reduced total production cost of peptides 3.3.2 Restraints 3.3.2.1 Increasing complexity of peptides is a huge challenge for API manufacturers 3.3.2.2 Lack of regulatory standards 3.3.3 Opportunities 3.3.3.1 Generic peptides market to flourish with patent cliff expected during the forecast period 3.3.3.2 Biotech firms collaborating with large pharmaceutical companies to explore further growth 3.4 Regulatory Scenario 3.5 Porter’s Five Forces Analysis: Global Peptide Therapeutics Market 3.5.1 Bargaining Power of Suppliers 3.5.2 Bargaining Power of Buyer 3.5.3 Threat of Substitutes 3.5.4 Threat of New Entrants 3.5.5 Competitive Rivalry 3.6 Event Impact Analysis 3.6.1 Event Impact Analysis: Global Peptide Therapeutics Market 3.7 Market Attractiveness Analysis 3.7.1 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013 3.8 Market Share Analysis Chapter 4 Global Peptide Therapeutics Market, by Applications 4.1 Introduction 4.1.1 Global Peptide Therapeutics Market Revenue, by Application, 2012 – 2020 (USD Million) 4.2 Cancer 4.2.1 Global Cancer Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 4.2.2 Zoladex (goserelin) 4.2.3 Velcade (bortezomib) 4.2.4 Lupron/ Enantone/ Eligard (leuprorelin) 4.2.5 Others 4.3 Cardiovascular 4.3.1 Global Cardiovascular Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 4.3.2 Angiomax (bivalirudin) 4.3.3 Integrilin (eptifibatide) 4.4 Central Nervous System 4.4.1 Global Central Nervous System Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
4.4.2 Copaxone (glatiramer) 4.5 Metabolic Disorders 4.5.1 Global Metabolic Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 4.5.2 Victoza (liraglutide) 4.5.3 Byetta (exenatide) 4.5.4 Others 4.6 Infection 4.6.1 Global Infection Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 4.6.2 Incivek (telaprevir) 4.6.3 Victrelis (boceprevir) 4.7 Hematological Disorders 4.7.1 Global Hematological Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 4.7.2 Firazyr (icatibant) 4.7.3 Kalbitor (ecallantide) 4.8 Gastrointestinal Disorders 4.8.1 Global Gastrointestinal Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 4.8.2 Gattex (teduglutide) 4.8.3 Linzess (linaclotide) 4.9 Respiratory Disorders 4.9.1 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 4.10 Acromegaly 4.10.1 Global Acromegaly Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million) 4.11 Other Applications 4.11.1 Global Other Applications Peptide Therapeutics market Revenue, 2012 - 2020 (USD Million) Chapter 5 Global Peptide Therapeutics Market, by Route of Administration 5.1 Introduction 5.1.1 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 2020 (USD Million) 5.2 Parenteral Route of Administration 5.2.1 Global Peptide Therapeutics Market Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD Million) 5.3 Oral Route of Administration 5.3.1 Global Peptide Therapeutics Market Revenue, by Oral Route of Administration, 2012 - 2020 (USD Million) Chapter 6 Global Peptide Therapeutics Market, by Marketing Status 6.1 Introduction 6.1.1 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million) 6.2 Branded Peptide Therapeutics 6.2.1 Global Branded Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 6.3 Generic Peptide Therapeutics 6.3.1 Global Generic Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
Chapter 7 Global Peptide Therapeutics Pipeline Overview 7.1 Introduction 7.1.1 Global Peptide Therapeutics Pipeline Overview Chapter 8 Global Peptide Therapeutics Market, by Geography 8.1 Introduction 8.1.1 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million) 8.2 North America 8.2.1 North America Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 8.3 Europe 8.3.1 Europe Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 8.4 Asia Pacific 8.4.1 Asia Pacific Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) 8.5 Rest of the World 8.5.1 Rest of the World Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million) Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418 Chapter 9 Recommendations 9.1 Rigorous research and development (R&D) would yield new products 9.2 Facility expansion in emerging economies 9.3 Rapid inorganic growth through acquisitions Chapter 10 Company Profiles 10.1 Amgen, Inc. 10.1.1 Company Overview 10.1.2 Financial Overview 10.1.3 Product Portfolio 10.1.4 Business Strategies 10.1.5 Recent Developments 10.2 AstraZeneca plc 10.2.1 Company Overview 10.2.2 Financial Overview 10.2.3 Product Portfolio 10.2.4 Business Strategies 10.2.5 Recent Developments 10.3 Bachem Holding AG 10.3.1 Company Overview 10.3.2 Financial Overview 10.3.3 Product Portfolio 10.3.4 Business Strategies 10.3.5 Recent Developments 10.4 CordenPharma International GmbH 10.4.1 Company Overview 10.4.2 Financial Overview 10.4.3 Product Portfolio 10.4.4 Business Strategies 10.4.5 Recent Developments 10.5 Eli Lilly and Company
10.5.1 Company Overview 10.5.2 Financial Overview 10.5.3 Product Portfolio 10.5.4 Business Strategies 10.5.5 Recent Developments 10.6 Ipsen S.A. 10.6.1 Company Overview 10.6.2 Financial Overview 10.6.3 Product Portfolio 10.6.4 Business Strategies 10.6.5 Recent Developments 10.7 Lonza Group Ltd. 10.7.1 Company Overview 10.7.2 Financial Overview 10.7.3 Product Portfolio 10.7.4 Business Strategies 10.7.5 Recent Developments 10.8 Merck & Co., Inc. 10.8.1 Company Overview 10.8.2 Financial Overview 10.8.3 Product Portfolio 10.8.4 Business Strategies 10.8.5 Recent Developments 10.9 Novartis AG 10.9.1 Company Overview 10.9.2 Financial Overview 10.9.3 Product Portfolio 10.9.4 Business Strategies 10.9.5 Recent Developments 10.10 Novo Nordisk A/S 10.10.1 Company Overview 10.10.2 Financial Overview 10.10.3 Product Portfolio 10.10.4 Business Strategies 10.10.5 Recent Developments 10.11 PolyPeptide Group 10.11.1 Company Overview 10.11.2 Financial Overview 10.11.3 Product Portfolio 10.11.4 Business Strategies 10.11.5 Recent Developments 10.12 Roche Holdings AG 10.12.1 Company Overview 10.12.2 Financial Overview 10.12.3 Product Portfolio 10.12.4 Business Strategies 10.12.5 Recent Developments 10.13 Sanofi 10.13.1 Company Overview 10.13.2 Financial Overview 10.13.3 Product Portfolio
10.13.4 Business Strategies 10.13.5 Recent Developments 10.14 Takeda Pharmaceutical Company Limited 10.14.1 Company Overview 10.14.2 Financial Overview 10.14.3 Product Portfolio 10.14.4 Business Strategies 10.14.5 Recent Developments 10.15 Teva Pharmaceutical Industries Ltd. 10.15.1 Company Overview 10.15.2 Financial Overview 10.15.3 Product Portfolio 10.15.4 Business Strategies 10.15.5 Recent Developments Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418 About Us: Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. Contact: Transparency Market Research Mr. Sudip.S 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/